Afacifenacin

Afacifenacin (SMP-986) is a potent, orally active, non-selective muscarinic receptor antagonist developed for the treatment of overactive bladder (OAB). It works by blocking muscarinic receptors and inhibiting the bladder afferent pathway, which may reduce urinary urgency, frequency, and incontinence. Afacifenacin also exhibits sodium channel blockade activity that contributes to its effects on abnormal nerve transmission to the central nervous system. The drug was created in-house by Sumitomo Pharma and has been evaluated in Phase 2 clinical trials for OAB. It has shown potential for a lower incidence of typical antimuscarinic side effects such as dry mouth[1][2][3][7][8].

Other names

afacifenacin fumarate